Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Biothervax SpA
Sponsor

Biothervax SpA

Siena 2457, 7610671

About the sponsor

Biothervax SpA is involved in clinical research on a recombinant Bacillus Calmette-Guérin platform designed to express the RSV nucleoprotein, with attention to vaccine safety and immune response in older adults.

  • RSV immunogenicity
  • Recombinant BCG vaccine development
  • Viral antigen expression

The research focus includes immune recognition of respiratory syncytial virus antigens in adults over 60 years of age.

About Specializations

Biothervax SpA runs clinical trials in conditions such as Respiratory syncytial virus infection, among others.

Recruiting now

Ongoing trials

Clinical trials run by this sponsor – those enrolling participants first.

Condition
Country
City
Type of trial
Recruitment status
Quick filters

1 clinical trial

Respiratory syncytial virus infection

Recruiting

Study on the Safety and Immune Response of rBCG-N-RSV Vaccine Compared to BCG Vaccine in Adults Over 60 with Respiratory Syncytial Virus (RSV) Concerns

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:18–64 years · 65+ years · Healthy volunteers
  • Substances:MYCOBACTERIUM BOVIS BACILLUS CALMETTE-GUÉRIN, STRAIN DANISH 1331, LIVE, EXPRESSING RESPIRATORY SYNCYTIAL VIRUS, NUCLEOPROTEIN
  • Sponsor:Biothervax SpA

Are you running a clinical trial?

Increase visibility for your trials and help patients find your site through our platform.

Join now →
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.